Patents by Inventor Martin Lepage

Martin Lepage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinin-based theranostic probes for solid cancers and uses thereof
    Patent number: 11213597
    Abstract: It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 4, 2022
    Assignee: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Fernand Gobeil, Brigitte Guerin, Martin Lepage, Robert Sabbagh, David Fortin
  • Controlled release systems and low dose androgens
    Patent number: 5861387
    Abstract: Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration) administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 19, 1999
    Assignee: Endorecherche Inc.
    Inventors: Fernand Labrie, Martin Lepage
  • Controlled release systems and low dose androgens
    Patent number: 5814340
    Abstract: Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration) administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 29, 1998
    Assignee: Endorecherche Inc.
    Inventors: Fernand Labrie, Martin Lepage
  • Controlled release systems and low dose androgens
    Patent number: 5629303
    Abstract: Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration)administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: May 13, 1997
    Assignee: Endorecherche Inc.
    Inventors: Fernand Labrie, Martin Lepage
  • Controlled release systems and low dose androgens
    Patent number: 5541172
    Abstract: Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration) administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 30, 1996
    Assignee: Endorecherche, Inc.
    Inventors: Fernand Labrie, Martin Lepage
  • Controlled release systems and low dose androgens
    Patent number: 5434146
    Abstract: Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolaR serum concentration) administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
    Type: Grant
    Filed: June 24, 1992
    Date of Patent: July 18, 1995
    Assignee: Endorecherche, Inc.
    Inventors: Fernand Labrie, Martin Lepage